Literature DB >> 28527305

Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study.

Marina Gradišer1, Maja Cigrovski Berković2, Ines Bilić-Ćurčić3.   

Abstract

We included diabetes type 1 (T1DM) patients with suboptimal glycemic control on morning application glargine (I-Glar) U100, switching them to U300. After six months improvement in HbA1c was observed, while hypoglycemic episodes decreased. Switch from I-Glar U100 to U300 could be a good therapeutic option for that subset of patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glargine U100; Glargine U300; Glycemic control; Hypoglycemia; T1DM

Mesh：

Substances：

Year:  2017        PMID： 28527305     DOI： 10.1016/j.diabres.2017.03.036

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  4 in total

1.  Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice.

Authors:  Florentino Carral San Laureano; Mariana Tomé Fernández-Ladreda; Ana Isabel Jiménez Millán; Concepción García Calzado; María Del Carmen Ayala Ortega
Journal:  J Investig Med       Date:  2021-03-26       Impact factor: 2.895

Review 2.  Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review.

Authors:  Vincent Woo; Lori Berard; Robert Roscoe
Journal:  Diabetes Ther       Date:  2020-09-17       Impact factor: 2.945

3.  A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA).

Authors:  T Pang; S C Bain; R Neil A Black; J G Boyle; J Elliott; A Holcombe; K C S Lee; C Mulligan; L Saunders; A Yousseif; M Baxter
Journal:  Diabet Med       Date:  2018-11-16       Impact factor: 4.359

4.  Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes.

Authors:  Junko Oya; Tomoko Nakagami; Yukiko Hasegawa; Aki Katamine; Yuichiro Kondo; Tetsuya Babazono
Journal:  J Diabetes Investig       Date:  2021-05-03       Impact factor: 4.232
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.